Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs New York Times Co — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while New York Times Co trades at $63.73 (market cap $10.28B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.9× New York Times Co's market cap, and New York Times Co pays a 1.44% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | NYT | |
|---|---|---|
Market Cap | $29.60B | $10.28B |
Sector | Health | Media |
52-Week High | $491.22 | $85.86 |
52-Week Low | $205.48 | $54.66 |
Enterprise Value | $27.56B | $9.67B |
Dividend Yield | — | 1.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
The New York Times (NYT) trades at $63.93, down 1.34% amid bearish technical signals despite strong Q2 2026 earnings beats. Revenue growth continues with 2025 revenue reaching $2.82B and net income margin expanding to 12.17%. The stock faces technical pressure with RSI at oversold levels near key support at $62-63, while analyst consensus remains cautious with 65% hold ratings.
NYT demonstrates solid fundamental growth with expanding profitability and digital subscription strength, but faces near-term headwinds from slowing subscriber growth and technical weakness. The $77.50 consensus price target suggests 21% upside potential, though execution risks and competitive pressures warrant monitoring for current investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
